Madrigal Pharmaceuticals (MDGL) Free Cash Flow (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Free Cash Flow for 17 consecutive years, with $19.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Free Cash Flow rose 140.54% year-over-year to $19.1 million; the TTM figure through Jun 2026 stood at -$206.3 million (up 33.11% YoY), while the FY2025 annual figure was -$190.0 million, up 58.42% from the prior year.
• Free Cash Flow rose to $19.1 million in Q2 2026 per MDGL's latest filing, from -$171.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $79.0 million in Q3 2025 and bottomed at -$171.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$75.0 million across 5 years, with a median of -$78.2 million in 2023.
• Annual changes were most pronounced in 2025 — Free Cash Flow soared 216.57% — and 2026, when it sank 92.69%.
• Madrigal Pharmaceuticals' Free Cash Flow stood at -$58.5 million in 2022, then sank by 38.3% to -$81.0 million in 2023, then retreated by 29.29% to -$104.7 million in 2024, then decreased by 27.12% to -$133.1 million in 2025, then surged by 114.34% to $19.1 million in 2026.
• Business Quant data shows MDGL's Free Cash Flow at $19.1 million in Q2 2026, -$171.3 million in Q1 2026, and -$133.1 million in Q4 2025.